Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs).

Psoriatic arthritis (PsA) is a long-term, inflammatory disease affecting the joints and where tendons and ligaments connect to the bones. It doesn't have a cure. But a growing number of treatments can ...

The incidence of serious adverse events did not differ significantly between combo therapy and monotherapy in patients with immune-mediated inflammatory diseases. However, specific combinations such ...

Please provide your email address to receive an email when new articles are posted on . Biologic disease-modifying antirheumatic drugs used to treat juvenile rheumatic diseases are excluded entirely ...

Rheumatoid arthritis (RA) treatment has made major strides over the past few decades — first with the use of disease-modifying anti-rheumatic drugs (DMARDs), then with the introduction of biologic ...

DMARDs are a medication that suppresses the immune system. People may take them to slow disease progression in autoimmune or inflammatory conditions, such as different types of arthritis. Inflammation ...

DMARDs, including TNF-alpha inhibitors, may relieve pain and inflammation and help prevent joint damage from rheumatoid arthritis (RA). TNF-alpha inhibitors block TNF-alpha, which causes joint pain ...

The medications your doctor prescribes will usually change over the course of time. If following the treat-to-target paradigm, your doctor will continually monitor your disease activity (with serial ...

Please provide your email address to receive an email when new articles are posted on . The American College of Rheumatology has released its updated treatment guidelines for rheumatoid arthritis, ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

This guidance updates and replaces NICE technology appraisal guidance 711 on guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs. Next review: This guidance will be ...

There is a commercial access agreement for tofacitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact PfizerUKAccess@pfizer.com ...